Efficacy of 20% Human Albumin in Reducing Pleural Effusion After Cardiopulmonary Bypass

PHASE4CompletedINTERVENTIONAL
Enrollment

70

Participants

Timeline

Start Date

September 1, 2022

Primary Completion Date

December 1, 2023

Study Completion Date

January 1, 2024

Conditions
Pleural Effusions Post Coronary Artery Bypass GraftHypoxiaHypoalbuminemia
Interventions
DRUG

Adding 100ml of 20% human albumin to cardiopulmonary bypass priming solution

"Adding albumin to the priming solution can help reduce hemodilution and consequent extracardiac complications by maintaining colloid oncotic pressure. Albumin helps counteract the intravascular fluid shift to the extravascular space and reduces the risk of complications associated with fluid imbalance.~Postoperative pulmonary complications following CPB can significantly impact postoperative outcomes. Patients developing PPC have prolonged mechanical ventilation, extended hospitalisation, longer ICU stays, and elevated postoperative mortality. One of the most common PPCs following CPB is pleural effusion.~Our primary objective was to evaluate the effectiveness of adding 100 ml of 20% human albumin to the CPB priming solution compared to standard priming, with a specific focus on its potential role in reducing the occurrence of pleural effusion."

Trial Locations (1)

LV1002

Pauls Stradiņš Clinical University Hospital, Riga

All Listed Sponsors
collaborator

Riga Stradins University

OTHER

lead

Pauls Stradins Clinical University Hospital

OTHER